A Randomised, Double-Blind, Double Observer, Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of Two Different Formulations of an Influenza A Vaccine (FP-01.1).
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2013
At a glance
- Drugs FP 01-Immune Targeting Systems (Primary) ; Adjuvants
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 11 Sep 2012 New trial record